Tagged with M&A

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series B+ funding for CAR-T therapies. Clinical updates include Bioheng’s CAR-T success in autoimmune diseases, Qyuns’ Phase III results for Crusekitug…

Germany The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered are Merck KGaA’s tie-up with JSR Life Sciences for its chromatography business, Bayer’s 12,000 layoffs, and STADA’s potential IPO.  …

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive HER2 ADC Phase III data, Biokin’s US$250 million milestone payment from BMS and HKEX IPO approval, and Haixi Pharma’s 36%…

China This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Kite Pharma’s US$1.64B in vivo CAR-T deal with Pregene, Xuanzhu Biopharma’s HKEX debut with a 172% grey market premium, Hansoh’s US$1.53B CDH17 ADC licensing to Roche, and Leads Biolabs’ US$1B autoimmune drug deal with Dianthus. Biokin secured a record…

China In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between…

Switzerland With over seven decades of innovation behind it, Lupin has evolved from an Indian pioneer in anti-tuberculosis therapies into a global pharmaceutical leader shaping the future of complex generics, speciality care, and biosimilars. As the company accelerates its European expansion, Laurent Renaudie shares how Lupin’s entrepreneurial culture, patient-centred mission, and…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Sichuan Biokin and Binhui Biopharma’s HKEX IPO filings, Betta Pharma’s third IPO attempt, Sirius Therapeutics–B’s HK$1.8B IPO, and Biocytogen’s STAR Market approval. Clinical updates include Eisai’s Leqembi approval for Alzheimer’s, CMS’s NDA plans for ruxolitinib, and RemeGen’s…

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights GenFleet Therapeutics’ HKEX IPO, Sciwind’s IPO filing for enoglutide, Biocytogen’s STAR Market approval, Hengrui’s HER2 ADC licensing deal with Glenmark, and AusperBio’s US$63M Series B2 financing. Clinical updates include AbbVie’s FL filing for Epcoritamab, Ascletis’ THRβ agonist…

China This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for its Parkinson’s cell therapy, and Rapafusyn’s USD 44mn Series A for molecular glues. On the clinical front, Junshi posts positive…

Switzerland New Idorsia CEO Srishti Gupta is emphasising “financial discipline” as she looks to turn around the fortunes of one of Europe’s top biotechs.   Challenging Times Gupta, who spent almost two decades at consultancy firm McKinsey, inherits a company that managed to launch three drugs in its first seven years…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…